How Does Retatrutide Compare to Tirzepatide and Semaglutide in Trial Data?
The three compounds form a receptor-coverage progression: Semaglutide activates only the GLP-1 receptor, Tirzepatide adds GIP receptor agonism on top of GLP-1, and Retatrutide adds a third receptor — glucagon — on top of both. Each additional receptor target is the basis for the research interest in whether more receptor coverage translates to larger effect sizes.
Published figures: Retatrutide's Phase 2 trial (Jastreboff et al., NEJM 2023) reported ≈24.2% mean weight reduction at the highest dose at 48 weeks; Tirzepatide's SURMOUNT-1 (NEJM 2022) reported ≈22.5% at 72 weeks; Semaglutide's STEP 1 (NEJM 2021) reported ≈14.9% at 68 weeks. These trials differ in duration, population, and dosing, so the numbers illustrate a trend across the drug class rather than a controlled direct comparison.
REVIVE LAB UAE stocks Retatrutide as a research peptide — it does not stock Tirzepatide or Semaglutide. This comparison reflects published clinical trial literature and is provided for research background only, not a therapeutic claim or recommendation.
| Compound (dose) | Receptor Profile | Pivotal Trial | Mean Weight Reduction |
|---|---|---|---|
| Retatrutide 12 mg | GLP-1 + GIP + Glucagon (triple) | Phase 2, NEJM 2023, 48 weeks | ≈ 24.2% |
| Tirzepatide 15 mg | GLP-1 + GIP (dual) | SURMOUNT-1, NEJM 2022, 72 weeks | ≈ 22.5% |
| Semaglutide 2.4 mg | GLP-1 (mono) | STEP 1, NEJM 2021, 68 weeks | ≈ 14.9% |
Purity ≥ 99.0% (HPLC) · COD, card or Binance Pay (5% off) Order Retatrutide UAE — Live Stock & Pricing